Regenerative Therapy for Visual Loss

360_F_86622840_pzygNkPkQL1vqYmgEB2tFZ533j9to3KU.jpg

 

Troflo (TP7193, TP0233) in opto-retinal degeneration

TP7193 or TP0233 in eye drops (‘Troflo’) is a proposed treatment for retinal disease, designed to delay the pathophysiological (non-proliferative) senescence associated with the progressive atrophic condition of posterior segment.

Indeed, the ocular fundus undergoing to atrophic-like diseases such as dry AMD (age-related macular degeneration) and glaucoma are still in need of feasible regenerative option.

Troflo is conceived either as Rx drug or as Medical Device pursuant MDR regulation (EU) 2017/745 or FDA 510(k).

Dry AMD

 

 

AMD is a common cause of severe loss of eyesight among people over 50. AMD affects the central vision, and the ability to see fine details as the central part of the retina (macula) is progressively damaged. In advanced stages, people lose their ability to drive, to see faces, and to read smaller print. Dry AMD is the most common type (80% of AMD) has unknown cause, although both genetic and environmental factors may play a role, wherein drusen accumulate in the basal retina. This happens as the light-sensitive cells in the macula slowly break down, generally one eye at a time. The loss of vision in this condition is usually slow and gradual, wherein the aging damage of the support membrane under the retina contributes to the dry AMD. No specific therapies have been developed for this high prevalent eye disease in the caucasian population.

In contrast, wet AMD is treated with anti-VEGF while a number of newer anti-angiogenic are under study. These agents are of little, if any use in dry AMD, which is otherwise characterized by thinning retina, fibrotic and anti-profilerative events in RPE cell and Bruch's membrane. 

Glaucoma

 

 

Glaucoma are progressive optic neuropathies driven by the degeneration of retinal ganglion cells and retinal nerve fiber layers that result in changes in the optical nerve head. Glaucoma is associated with intraocular pressure (IOP)-related damage to the optic nerve, and the loss of retinal ganglion cells. Both primary and secondary glaucoma have two major subtypes (open-angle and angle-closure) according to the underlying anatomy and pathophysiology. Primary or idiopathic glaucoma has no identifiable cause while secondary glaucoma has an identifiable cause in the increased IOP causing the optic nerve damage. Open-angle glaucoma is classified into primary open-angle glaucoma (POAG) when IOP progress to the optic nerve; normal-tension glaucoma (NTG) when normal IOP progress to optic neuropathy; and secondary open-angle glaucoma when elevated IOP and/or optic neuropathy. No options, beside the preventive IPO-lowering agents, are presently available to restore a neurotrophic status within the damaged RGC and optic nerve and/or associated vascularity.